Results 11 to 20 of about 202 (68)
ChemMedChem, Volume 20, Issue 23, November 28, 2025.Sticky end‐type antithrombin aptamer, composed of two short hybridizable segments, is developed as a potential alternative to conventional anticoagulant drugs. The obtained bivalent aptamer surpasses existing long bivalent aptamers in anticoagulant activity and serum stability, offering advantages in synthesis efficiency and cost‐effectiveness. Aptamer
Maasa Yokomori +4 more
wiley +1 more source
Angewandte Chemie, Volume 136, Issue 16, April 15, 2024.Aptamers are highly structured, single‐stranded oligonucleotides that bind to specific targets with high affinity and selectivity. We provide a comprehensive overview of aptamer development strategies that can help facilitate their translation into real world applications, including discussions on how certain secondary structures can be used as ...
Alex Brown +4 more
wiley +2 more sources
Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration
Advanced Science, Volume 12, Issue 39, October 20, 2025.There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz +4 more
wiley +1 more source
Advanced Science, Volume 12, Issue 35, September 18, 2025.A phosphorothioate‐modified aptamer PTf‐SRiApt capable of disrupting “undruggable” transcription factor SCAF4‐POLR2A interaction with high inhibitory activity and biological stability is presented here. Through this inhibition, PTf‐SRiApt successfully arrested cell cycle progression, induced cell death, and elevated immune recruitment in SCAF4‐POLR2A ...
Liyan Fei +13 more
wiley +1 more source
Recent Advancements in the Treatment of Age‐Related Macular Degeneration
Med Research, Volume 1, Issue 2, Page 151-169, September 2025.ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu +10 more
wiley +1 more source
The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina
Advanced Functional Materials, Volume 35, Issue 3, January 15, 2025.Gene therapy is often the only hope for a cure for many retinal diseases. However, due to the unique anatomy of the eye, the introduction of such genes or nucleic acids is extremely challenging. This article presents various diseases, barriers, and challenges as well as methods and different nanomaterials that are used to deliver nucleic acids into the
José Hurst +2 more
wiley +1 more source
Aptasensors and Advancement in Molecular Recognition Technology
Advanced Materials Technologies, Volume 10, Issue 1, January 8, 2025.This review summarizes how aptamers (chemical antibodies)‐based biosensors are developed and applied to biological and biomedical research as well as clinical diagnostics. How a nucleic acid‐based biosensor platform is poised to become the next generation of sensitive and cost‐effective technology will be showcased, shaping the future of biosensing ...
Rajindra Napit +10 more
wiley +1 more source
Complement‐targeted therapeutics: Are we there yet, or just getting started?
European Journal of Immunology, Volume 54, Issue 12, December 2024.After a hesitant start, the number of available therapeutics that target the human complement system has surged from one to a dozen drugs in less than 20 years. Meanwhile, the clinical arsenal encompasses treatment modalities directed to several targets for the therapy of a steadily growing spectrum of complement‐related disorders. Abstract Therapeutic
Daniel Ricklin
wiley +1 more source
Unlocking the Potential of Chemically Modified Nucleic Acid Therapeutics
Advanced Therapeutics, Volume 7, Issue 11, November 2024.The advancements in nucleic acid therapeutics are highlighted, focusing on chemical modifications and bioconjugation techniques that enhance stability, binding affinity, and targeted delivery. Recent literature and clinical applications emphasize the role of backbone, ribose, base modifications, and bioconjugation strategies like N‐acetylgalactosamine (
Jingjing Gao +10 more
wiley +1 more source
The complement system: A key player in the host response to infections
European Journal of Immunology, Volume 54, Issue 11, November 2024.Duality of the complement system during infection: An adequate immune defense clears the infection and restores tissue resilience, whereas a maladaptive response due to complement hyperactivation results in hyperinflammation and tissue injury, as seen in sepsis and pneumonia.
Archana Jayaraman +2 more
wiley +1 more source